245 related articles for article (PubMed ID: 19854710)
1. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study.
Seitz M; Reichenbach S; Möller B; Zwahlen M; Villiger PM; Dufour JF
Ann Rheum Dis; 2010 Jun; 69(6):1148-50. PubMed ID: 19854710
[TBL] [Abstract][Full Text] [Related]
2. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Gladman DD
Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
[TBL] [Abstract][Full Text] [Related]
5. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
[TBL] [Abstract][Full Text] [Related]
6. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
Lertnawapan R; Chonprasertsuk S; Siramolpiwat S
Int J Rheum Dis; 2019 Feb; 22(2):214-221. PubMed ID: 30565876
[TBL] [Abstract][Full Text] [Related]
7. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
9. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
10. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
Helliwell PS; Taylor WJ;
J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
[TBL] [Abstract][Full Text] [Related]
11. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis.
Deyab G; Hokstad I; Whist JE; Smastuen MC; Agewall S; Lyberg T; Ronda N; Mikkelsen K; Hjeltnes G; Hollan I
Arthritis Res Ther; 2017 Oct; 19(1):232. PubMed ID: 29041979
[TBL] [Abstract][Full Text] [Related]
13. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
[TBL] [Abstract][Full Text] [Related]
14. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.
Mor A; Bingham CO; Kishimoto M; Izmirly PM; Greenberg JD; Reddy S; Rosenthal PB
Ann Rheum Dis; 2008 Apr; 67(4):462-5. PubMed ID: 17711866
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
Amital H; Arnson Y; Chodick G; Shalev V
Rheumatology (Oxford); 2009 Sep; 48(9):1107-10. PubMed ID: 19578136
[TBL] [Abstract][Full Text] [Related]
17. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
[TBL] [Abstract][Full Text] [Related]
19. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
20. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]